{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:57Z","timestamp":1787020857399,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tubulointerstitial fibrosis (TIF) is one of the main pathological features of various progressive renal damages and chronic kidney diseases. Mesenchymal stromal cells (MSCs) have been verified with significant improvement in the therapy of fibrosis diseases, but the mechanism is still unclear. We attempted to explore the new mechanism and therapeutic target of MSCs against renal fibrosis based on renal proteomics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TIF model was induced by adenine gavage. Bone marrow-derived MSCs was injected by tail vein after modeling. Renal function and fibrosis related parameters were assessed by Masson, Sirius red, immunohistochemistry, and western blot. Renal proteomics was analyzed using iTRAQ-based mass spectrometry. Further possible mechanism was explored by transfected galectin-3 gene for knockdown (Gal-3 KD) and overexpression (Gal-3 OE) in HK-2 cells with lentiviral vector.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MSCs treatment clearly decreased the expression of \u03b1-SMA, collagen type I, II, III, TGF-\u03b21, Kim-1, p-Smad2\/3, IL-6, IL-1\u03b2, and TNF\u03b1 compared with model rats, while p38 MAPK increased. Proteomics showed that only 40 proteins exhibited significant differences (30 upregulated, 10 downregulated) compared MSCs group with the model group. Galectin-3 was downregulated significantly in renal tissues and TGF-\u03b21-induced rat tubular epithelial cells and interstitial fibroblasts, consistent with the iTRAQ results. Gal-3 KD notably inhibited the expression of p-Akt, p-GSK3\u03b2 and snail in TGF-\u03b21-induced HK-2 cells fibrosis. On the contrary, Gal-3 OE obviously increased the expression of p-Akt, p-GSK3\u03b2 and snail.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The mechanism of MSCs anti-renal fibrosis was probably mediated by galectin-3\/Akt\/GSK3\u03b2\/Snail signaling pathway. Galectin-3 may be a valuable target for treating renal fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-021-02429-z","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T04:03:01Z","timestamp":1626408181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["RETRACTED ARTICLE: Mesenchymal stem cells ameliorate renal fibrosis by galectin-3\/Akt\/GSK3\u03b2\/Snail signaling pathway in adenine-induced nephropathy rat"],"prefix":"10.1186","volume":"12","author":[{"given":"Huajun","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianlin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1810-1849","authenticated-orcid":false,"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"2429_CR1","doi-asserted-by":"publisher","first-page":"8937657","DOI":"10.1155\/2020\/8937657","volume":"2020","author":"E Vazquez-Mendez","year":"2020","unstructured":"Vazquez-Mendez E, Gutierrez-Mercado Y, Mendieta-Condado E, Galvez-Gastelum FJ, Esquivel-Solis H, Sanchez-Toscano Y, et al. Recombinant erythropoietin provides protection against renal fibrosis in adenine-induced chronic kidney disease. Mediators Inflamm. 2020;2020:8937657.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"2429_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.9758\/cpn.2016.14.4.391","volume":"14","author":"T Tomita","year":"2016","unstructured":"Tomita T, Goto H, Sumiya K, Yoshida T, Tanaka K, Kohda Y. Efficacy of adenine in the treatment of leukopenia and neutropenia associated with an overdose of antipsychotics or discontinuation of lithium carbonate administration: three case studies. Clin Psychopharmacol Neurosci. 2016;14(4):391\u20135. https:\/\/doi.org\/10.9758\/cpn.2016.14.4.391.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"2429_CR3","doi-asserted-by":"publisher","first-page":"15482","DOI":"10.1038\/srep15482","volume":"5","author":"AC Boon","year":"2015","unstructured":"Boon AC, Lam AK, Gopalan V, Benzie IF, Briskey D, Coombes JS, et al. Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure. Sci Rep. 2015;5(1):15482. https:\/\/doi.org\/10.1038\/srep15482.","journal-title":"Sci Rep"},{"issue":"2","key":"2429_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.stem.2017.07.011","volume":"21","author":"E El Agha","year":"2017","unstructured":"El Agha E, Kramann R, Schneider RK, Li X, Seeger W, Humphreys BD, et al. Mesenchymal stem cells in fibrotic disease. Cell Stem Cell. 2017;21(2):166\u201377. https:\/\/doi.org\/10.1016\/j.stem.2017.07.011.","journal-title":"Cell Stem Cell"},{"key":"2429_CR5","doi-asserted-by":"publisher","first-page":"8031718","DOI":"10.1155\/2018\/8031718","volume":"2018","author":"REB Fitzsimmons","year":"2018","unstructured":"Fitzsimmons REB, Mazurek MS, Soos A, Simmons CA. Mesenchymal stromal\/stem cells in regenerative medicine and tissue engineering. Stem Cells Int. 2018;2018:8031718.","journal-title":"Stem Cells Int"},{"issue":"1","key":"2429_CR6","doi-asserted-by":"publisher","first-page":"14036","DOI":"10.1038\/s41598-017-14492-9","volume":"7","author":"S Yokote","year":"2017","unstructured":"Yokote S, Katsuoka Y, Yamada A, Ohkido I, Yokoo T. Effect of adipose-derived mesenchymal stem cell transplantation on vascular calcification in rats with adenine-induced kidney disease. Sci Rep. 2017;7(1):14036. https:\/\/doi.org\/10.1038\/s41598-017-14492-9.","journal-title":"Sci Rep"},{"issue":"8","key":"2429_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.jcyt.2016.05.004","volume":"18","author":"HH Anan","year":"2016","unstructured":"Anan HH, Zidan RA, Shaheen MA, Abd-El Fattah EA. Therapeutic efficacy of bone marrow derived mesenchymal stromal cells versus losartan on adriamycin-induced renal cortical injury in adult albino rats. Cytotherapy. 2016;18(8):970\u201384. https:\/\/doi.org\/10.1016\/j.jcyt.2016.05.004.","journal-title":"Cytotherapy"},{"issue":"6","key":"2429_CR8","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jcyt.2014.01.004","volume":"16","author":"R Moghadasali","year":"2014","unstructured":"Moghadasali R, Azarnia M, Hajinasrollah M, Arghani H, Nassiri SM, Molazem M, et al. Intra-renal arterial injection of autologous bone marrow mesenchymal stromal cells ameliorates cisplatin-induced acute kidney injury in a rhesus Macaque mulatta monkey model. Cytotherapy. 2014;16(6):734\u201349. https:\/\/doi.org\/10.1016\/j.jcyt.2014.01.004.","journal-title":"Cytotherapy"},{"issue":"4","key":"2429_CR9","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1021\/acsnano.9b08207","volume":"14","author":"H Cao","year":"2020","unstructured":"Cao H, Cheng Y, Gao H, Zhuang J, Zhang W, Bian Q, et al. In vivo tracking of mesenchymal stem cell-derived extracellular vesicles improving mitochondrial function in renal ischemia-reperfusion injury. ACS Nano. 2020;14(4):4014\u201326. https:\/\/doi.org\/10.1021\/acsnano.9b08207.","journal-title":"ACS Nano"},{"issue":"59","key":"2429_CR10","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.18632\/oncotarget.21727","volume":"8","author":"CH Chen","year":"2017","unstructured":"Chen CH, Cheng BC, Chen KH, Shao PL, Sung PH, Chiang HJ, et al. Combination therapy of exendin-4 and allogenic adipose-derived mesenchymal stem cell preserved renal function in a chronic kidney disease and sepsis syndrome setting in rats. Oncotarget. 2017;8(59):100002\u201320. https:\/\/doi.org\/10.18632\/oncotarget.21727.","journal-title":"Oncotarget"},{"issue":"8","key":"2429_CR11","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1021\/acs.jproteome.0c00226","volume":"19","author":"Z Yang","year":"2020","unstructured":"Yang Z, Shen X, Chen D, Sun L. Toward a universal sample preparation method for denaturing top-down proteomics of complex proteomes. J Proteome Res. 2020;19(8):3315\u201325. https:\/\/doi.org\/10.1021\/acs.jproteome.0c00226.","journal-title":"J Proteome Res"},{"issue":"2","key":"2429_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3892\/ijmm.2017.3311","volume":"41","author":"R Dong","year":"2018","unstructured":"Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018;41(2):599\u2013614. https:\/\/doi.org\/10.3892\/ijmm.2017.3311.","journal-title":"Int J Mol Med"},{"issue":"41","key":"2429_CR13","doi-asserted-by":"publisher","first-page":"70707","DOI":"10.18632\/oncotarget.19979","volume":"8","author":"F Zhu","year":"2017","unstructured":"Zhu F, OLS CLS, Pei G, Hu Z, Yang J, Zhu H, et al. Adipose-derived mesenchymal stem cells employed exosomes to attenuate AKI-CKD transition through tubular epithelial cell dependent Sox9 activation. Oncotarget. 2017;8(41):70707\u201326. https:\/\/doi.org\/10.18632\/oncotarget.19979.","journal-title":"Oncotarget"},{"issue":"8","key":"2429_CR14","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s11255-018-1844-7","volume":"50","author":"M Tang","year":"2018","unstructured":"Tang M, Zhang K, Li Y, He QH, Li GQ, Zheng QY, et al. Mesenchymal stem cells alleviate acute kidney injury by down-regulating C5a\/C5aR pathway activation. Int Urol Nephrol. 2018;50(8):1545\u201353. https:\/\/doi.org\/10.1007\/s11255-018-1844-7.","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"2429_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jcyt.2018.02.368","volume":"20","author":"A Makhlough","year":"2018","unstructured":"Makhlough A, Shekarchian S, Moghadasali R, Einollahi B, Dastgheib M, Janbabaee G, et al. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: a safety study with 18\u2009months of follow-up. Cytotherapy. 2018;20(5):660\u20139. https:\/\/doi.org\/10.1016\/j.jcyt.2018.02.368.","journal-title":"Cytotherapy"},{"issue":"2","key":"2429_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/scrt198","volume":"4","author":"JM Quimby","year":"2013","unstructured":"Quimby JM, Webb TL, Habenicht LM, Dow SW. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. Stem Cell Res Ther. 2013;4(2):48. https:\/\/doi.org\/10.1186\/scrt198.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"2429_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3727\/096368915X689622","volume":"25","author":"T Squillaro","year":"2016","unstructured":"Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829\u201348. https:\/\/doi.org\/10.3727\/096368915X689622.","journal-title":"Cell Transplant"},{"issue":"9","key":"2429_CR18","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.transproceed.2017.09.038","volume":"49","author":"P Yu","year":"2017","unstructured":"Yu P, Wang Z, Liu Y, Xiao Z, Guo Y, Li M, et al. Marrow mesenchymal stem cells effectively reduce histologic changes in a rat model of chronic renal allograft rejection. Transplant Proc. 2017;49(9):2194\u2013203. https:\/\/doi.org\/10.1016\/j.transproceed.2017.09.038.","journal-title":"Transplant Proc"},{"issue":"1","key":"2429_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000381515","volume":"1","author":"S Tanaka","year":"2015","unstructured":"Tanaka S, Tanaka T, Nangaku M. Hypoxia and dysregulated angiogenesis in kidney disease. Kidney Dis (Basel). 2015;1(1):80\u20139. https:\/\/doi.org\/10.1159\/000381515.","journal-title":"Kidney Dis (Basel)"},{"issue":"8","key":"2429_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/nep.13099","volume":"23","author":"B Liu","year":"2018","unstructured":"Liu B, Ding FX, Liu Y, Xiong G, Lin T, He DW, et al. Human umbilical cord-derived mesenchymal stem cells conditioned medium attenuate interstitial fibrosis and stimulate the repair of tubular epithelial cells in an irreversible model of unilateral ureteral obstruction. Nephrology (Carlton). 2018;23(8):728\u201336. https:\/\/doi.org\/10.1111\/nep.13099.","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"2429_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s11255-019-02123-3","volume":"51","author":"T Zhang","year":"2019","unstructured":"Zhang T, Cao S, Yang H, Li J. Prognostic impact of galectin-3 in chronic kidney disease patients: a systematic review and meta-analysis. Int Urol Nephrol. 2019;51(6):1005\u201311. https:\/\/doi.org\/10.1007\/s11255-019-02123-3.","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"2429_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ekir.2018.09.013","volume":"4","author":"ML Alam","year":"2019","unstructured":"Alam ML, Katz R, Bellovich KA, Bhat ZY, Brosius FC, de Boer IH, et al. Soluble ST2 and galectin-3 and progression of CKD. Kidney Int Rep. 2019;4(1):103\u201311. https:\/\/doi.org\/10.1016\/j.ekir.2018.09.013.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2429_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.kint.2017.06.028","volume":"93","author":"CM Rebholz","year":"2018","unstructured":"Rebholz CM, Selvin E, Liang M, Ballantyne CM, Hoogeveen RC, Aguilar D, et al. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int. 2018;93(1):252\u20139. https:\/\/doi.org\/10.1016\/j.kint.2017.06.028.","journal-title":"Kidney Int"},{"key":"2429_CR24","doi-asserted-by":"crossref","unstructured":"Li HY, Yang S, Li JC, Feng JX. Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity. Biosci Rep 2018;38(6):BSR20181803.","DOI":"10.1042\/BSR20181803"},{"key":"2429_CR25","doi-asserted-by":"crossref","unstructured":"Rodriguez-Ortiz ME, Pontillo C, Rodriguez M, Zurbig P, Mischak H, Ortiz A. Novel urinary biomarkers for improved prediction of progressive egfr loss in early chronic kidney disease stages and in high risk individuals without chronic kidney disease. Sci Rep-Uk. 2018;8(1):15940.","DOI":"10.1038\/s41598-018-34386-8"},{"key":"2429_CR26","doi-asserted-by":"crossref","unstructured":"Hara A, Niwa M, Noguchi K, Kanayama T, Niwa A, Matsuo M, Hatano Y, Tomita H. Galectin-3 as a next-generation biomarker for detecting early stage of various diseases. Biomolecules 2020;10(3):389.","DOI":"10.3390\/biom10030389"},{"issue":"1","key":"2429_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.autrev.2016.09.023","volume":"16","author":"F Saccon","year":"2017","unstructured":"Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A. Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmun Rev. 2017;16(1):34\u201347. https:\/\/doi.org\/10.1016\/j.autrev.2016.09.023.","journal-title":"Autoimmun Rev"},{"key":"2429_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.cca.2020.07.040","volume":"510","author":"X Han","year":"2020","unstructured":"Han X, Zhang S, Chen Z, Adhikari BK, Zhang Y, Zhang J, et al. Cardiac biomarkers of heart failure in chronic kidney disease. Clin Chim Acta. 2020;510:298\u2013310. https:\/\/doi.org\/10.1016\/j.cca.2020.07.040.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"2429_CR29","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.2337\/dc15-1182","volume":"39","author":"G Musso","year":"2016","unstructured":"Musso G, Cassader M, Cohney S, De Michieli F, Pinach S, Saba F, et al. Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities. Diabetes Care. 2016;39(10):1830\u201345. https:\/\/doi.org\/10.2337\/dc15-1182.","journal-title":"Diabetes Care"},{"key":"2429_CR30","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.12688\/f1000research.25979.2","volume":"9","author":"JL Caniglia","year":"2020","unstructured":"Caniglia JL, Asuthkar S, Tsung AJ, Guda MR, Velpula KK. Immunopathology of galectin-3: an increasingly promising target in COVID-19. F1000Res. 2020;9:1078.","journal-title":"F1000Res"},{"key":"2429_CR31","doi-asserted-by":"publisher","first-page":"4150735","DOI":"10.1155\/2020\/4150735","volume":"2020","author":"L Deng","year":"2020","unstructured":"Deng L, Chen T, Xu H, Li Y, Deng M, Mo D, et al. The expression of Snail, Galectin-3, and IGF1R in the differential diagnosis of benign and malignant pheochromocytoma and paraganglioma. Biomed Res Int. 2020;2020:4150735.","journal-title":"Biomed Res Int"},{"issue":"4","key":"2429_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/ijms17040565","volume":"17","author":"SC Chen","year":"2016","unstructured":"Chen SC, Kuo PL. The role of galectin-3 in the kidneys. Int J Mol Sci. 2016;17(4):565. https:\/\/doi.org\/10.3390\/ijms17040565.","journal-title":"Int J Mol Sci"},{"key":"2429_CR33","doi-asserted-by":"crossref","unstructured":"Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM. Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander?. Am J Nephrol. 2016;43(5):305-317.\u00a0https:\/\/doi.org\/10.1159\/000446376","DOI":"10.1159\/000446376"},{"issue":"5","key":"2429_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000446376","volume":"43","author":"V Desmedt","year":"2016","unstructured":"Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM. Galectin-3 in renal pathology: more than just an innocent bystander. Am J Nephrol. 2016;43(5):305\u201317. https:\/\/doi.org\/10.1159\/000446376.","journal-title":"Am J Nephrol"}],"updated-by":[{"DOI":"10.1186\/s13287-024-03668-6","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"record-id":"52567"},{"DOI":"10.1186\/s13287-024-03668-6","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000}}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-021-02429-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T10:13:16Z","timestamp":1709374396000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02429-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2429"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02429-z","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13287-024-03668-6","URL":"https:\/\/doi.org\/10.1186\/s13287-024-03668-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiment protocols were approved by the Ethic Committee of Southwest Medical University (201803147 SWMU).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work. There is no professional or other personal interest in any product, service, and\/or company that could be construed as influencing the position presented in the manuscript entitled.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}